Table 3.
Association between various patient characteristics and high EDSS score (>4.5) at last presentation.
| High EDSS Score at Last Presentation | ||
|---|---|---|
| OR | p-Value | |
| Usage of escalation therapies a | ||
| No | reference | |
| Yes | 1.60 (0.45–6.14) | 0.48 |
| Usage of high efficacy therapies b | ||
| No | reference | |
| Yes | 2.64 (0.87–8.33) | 0.09 |
| Smoker c | ||
| No | reference | |
| Yes | 2.44 (1.36–6.12) | 0.01 |
| Medical evaluation by Neurologist c | ||
| No | reference | |
| Yes | 0.40 (0.16–0.90) | 0.04 |
| Adherence to DMT c | ||
| Yes | reference | |
| No | 0.73 (0.31–1.62) | 0.43 |
| Time to diagnosis c | ||
| <=12 months | reference | |
| >12 months | 1.73 (0.75–4.01) | 0.2 |
a adjusted for adherence, smoking, race and age and EDSS at diagnosis; b adjusted for prior exposure to escalation therapies, adherence, smoking, race, age and EDSS at diagnosis; c adjusted for age and race.